|Last Price||Today's Change||52-Week Range||Trading Volume|
|120.02||1.34 (+1.13%)||66.85 - 129.06||5.2 million (Below Avg)|
Market data as of 4:14PM 03/30/15. Quotes are delayed by at least 15 min.
Positive Results from Phase III Study Evaluating Oral OTEZLA® (Apremilast) or Injectable Etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at AAD
03/20/2015 1:00 PM ET